A Phase 1b/2 trial to evaluate the efficacy and safety of etrumadenant-based treatment combinations in participants with metastatic castration-resistant prostate cancer.
CD73 is the primary enzymatic producer of immunosuppressive adenosine in the tumor microenvironment, and high CD73 expression is associated with significantly poorer prognosis in several tumor types.
AB680 is designed to provide differential benefits relative to monoclonal antibodies, such as greater inhibition of CD73 enzymatic activity (both soluble and cell-bound) and deeper tumor penetration. By effectively eliminating CD73-derived adenosine, AB680 may improve the efficacy of treatment approaches proven to elicit anti-cancer immune responses (eg, with anti-PD-1 and/or platinum-based chemotherapy).
AB680 is the first small molecule CD73 inhibitor in the clinic and has demonstrated a favorable safety profile with a long half-life.
Castration-resistant prostate cancer (ARC-6)
Pancreatic adenocarcinoma (ARC-8)